Investigation of Molecular Mechanisms of Aminoglycoside Resistance in Salmonella

The spread of aminoglycoside resistance phenotype and respective genetic resistance determinants was evaluated in 243 Salmonella strains isolated within 1948-2010 and stored in the Culture Collection of the Russian State Research Institute for Control, Standardization and Certification of Veterinary Preparations (Moscow). The Salmonella strains showed resistance to streptomycin and gentamicin in 3.7% (n=9) and 0.8% (n=2) of the isolates respectively. Intermediate resistance to streptomycin was recorded in 9.9% (n=24) of the isolates. To detect the genes responsible for the aminoglycoside resistance, primers for aadAl, aadA2, aadB, aphAl, aphA3, sat, strA, strB, aphA, aacC, rmtB, armA and rpsL genes amplification and sequencing were designed. The strains with lower susceptibility to streptomycin harbored aadAl, aadA2, strA, strB resistance genes encoding enzymes for aminoglicoside modification and rpsL mutant allele (K42N, G91D). Genetic mechanisms able to explain the gentamicin resistance development were not detected. Some strains carried genetic markers of streptomycine resistance but had no clinically sufficient resistance to it. In this regard, genetic testing is essential for prevention of drug resistance spreading due to horizontal transfer of genes in microbial population.

Salmonella, Salmonella, resistance, aminoglycosides, streptomycin, gentamicin

1. World Health Organisation - Programmes and projects - Media centre - Fact sheets - Fact sheet №139. http://www.who.int/mediacentre/factsheets/fs139/en/ - Revised April 2005.

2. Онищенко Г.Г. Постановление № 21 от 19 03.2010 Зарегистрировано Министерством Юстиции Российской Федерации № 16959 от 22.04. 2010 г.

3. Miko A., Pries K., Schroeter A. et al. J Antimicrob Chemother 2005; 56: 1025-1033.

4. Angulo F., Nargund V., Chiller T. J Vet Med B Infect Dis Vet Public Health 2004; 51: 374-379.

5. Aarestrup F.M. J Vet Med B 2004; 51: 380-388.

6. Wray C., Gnanou J.C. Int J Antimicrob Agents 2000; 14: 291-294.

7. Paulander W., Maisnier-Patin S., Andersson D.I. Genetics 2009; 183: 2: 539-546.

8. Bogaerts P., Galimand M., Bauraing C. et al. J Antimicrob Chemother 2007; 59: 3: 459-464.

9. Trunck L.A., Propst K.L., Wuthiekanun V. et al. PloS Negl Trop Dis 2009; 3: 9: e519.

10. Сидоренко С.В. Consilium Medicum 2007; 9: 1. Публикация на сайте издательства http://www.consilium-medicum.com/medicum/article/15013/

11. Bauer A.W., Kirby W.M.M., Sherris J.C. et al. Am J Clin Pathol 1966; 45: 4: 493-496.

12. Performance Standards for Antimicrobial Disk Susceptibility Tests; Approved Standard - Tenth Edition. Clinical and Laboratory Standards Institute, 940 West Valley Road, Suite 1400, Wayne, Pennsylvania 19087-1898 USA, 2009.

13. Регистр лекарственных средств России. Публикация на сайте издательства http://www.rlsnet.ru/mnn_index_id_1605.htm

14. Aarestrup F.M. Basic & Clinical Pharmacology & Toxicology 2005; 96: 271-281.

15. Regula G. et al. J Antimicrob Chemother 2009; 63: 805-811.

16. Shaw K.J., Rather P.N., Hare R.S. et al. Microbiological Reviews 1993; 57: 1: 138-163.

17. Pezzella C., Ricci A., DiGiannatale E., Luzzi I., Carattoli A. Antimicrob Agents Chemother 2004; 48: 903-908.

18. Sundel M., Norström M. J Antimicrob Chemother 2005; 56: 87-90.

19. Smith C.J., Owen C., Kirby L. Mol Microbiol 1992; 16: 2287-2297.